All Biotechnology articles
-
Article
Bayer promotes head of litigation to general counsel
Life sciences company Bayer announced the promotion of Vice President and Global Head of Litigation William Dodero to senior vice president and general counsel.
-
ArticlePharma, whistleblower lessons learned from $900M Biogen settlement
Experts discuss the ramifications of Biogen’s $900 million settlement for False Claims Act violations, including the $266.4 million whistleblower bounty in the case believed to be the largest single award under any government program.
-
Article
Biogen finalizes $900M settlement in false claims whistleblower suit
Biogen finalized a $900 million settlement concerning alleged kickbacks it paid to doctors to induce them to prescribe the company’s drugs and not those of its competitors.
-
Article
Cullinan Oncology names chief legal, compliance officer
Biotechnology researcher Cullinan Oncology announced the appointment of Jacquelyn Sumer as chief legal and compliance officer and corporate secretary.
-
Article
DermTech appoints chief compliance officer
Biotechnology research firm DermTech announced the appointment of Jennifer Eilemberg as chief compliance officer.
-
Article
Biogen discloses $900M agreement in whistleblower kickback suit
Massachusetts-based biotechnology firm Biogen reached a $900 million agreement in principle to resolve a False Claims Act lawsuit brought by a whistleblower alleging the payment of unlawful kickbacks to physicians.
-
Article
Ocugen appoints chief accounting officer
Ocugen, a clinical-stage biopharmaceutical company, announced the appointment of Jessica Crespo as chief accounting officer and senior vice president, finance.
-
Article
Opentrons Labworks names chief legal and compliance officer
Biotechnology company Opentrons Labworks announced the appointment of Veleka Peeples-Dyer as chief legal and compliance officer.
-
Article
SEC notifies five Chinese companies of HFCAA noncompliance
The Securities and Exchange Commission has notified five China-based public companies they could be delisted from U.S. stock exchanges if they do not allow their audits to be inspected by the Public Company Accounting Oversight Board.
-
Article
Vaxart appoints general counsel
Vaxart, a clinical-stage biotechnology company, appointed Edward Berg as the company’s first in-house general counsel.
-
Article
Veracyte appoints chief accounting officer
Veracyte, a global diagnostics company, has appointed Jonathan Wygant as chief accounting officer.
-
Article
Biocept adds chief compliance officer
Biocept, a provider of molecular diagnostic assays, products, and services, announced the appointment of Darrell Taylor as senior vice president, general counsel and chief compliance officer.
-
Article
Cabaletta Bio appoints chief compliance officer
Clinical-stage biotechnology company Cabaletta Bio promoted Heather Harte-Hall to the role of chief compliance officer.
-
Article
Twist Bioscience appoints chief ethics and compliance officer
Synthetic biology and genomics company Twist Bioscience Corporation has appointed Dennis Cho as senior vice president, general counsel, and chief ethics and compliance officer.
-
Article
Cherry Bekaert audit partner facing SEC scrutiny over MiMedx fraud case
The Securities and Exchange Commission is considering whether to pursue enforcement against a certified public accountant for his alleged role in an accounting fraud case the agency brought against biotech company MiMedx Group.
-
Article
Axogen names new chief compliance officer
Axogen, a developer of surgical solutions, announced the appointment of Brad Ottinger as general counsel and chief compliance officer to replace the retiring Greg Freitag.
-
Article
MiMedx names new accounting chief post fraud settlement
Biotech company MiMedx Group, which last November settled an alleged case of accounting fraud with the SEC, announced the appointment of William Phelan as senior vice president and chief accounting officer.
-
Article
Imara appoints general counsel
Biopharmaceutical firm Imara announced the appointment of Stephen Migausky as senior vice president, legal and general counsel.
-
Article
FTC, FDA to enhance antitrust oversight in biologics market
The Federal Trade Commission and Food and Drug Administration have signaled they will be increasing their oversight of any potential antitrust behavior in the biologics market.
-
Article
SEC charges MiMedx Group with accounting fraud
Biotech company MiMedx Group and three of its former top executives have been charged with defrauding investors. In response, MiMedx reshuffled its management team, including the appointment of a new general counsel and secretary.
